BAM
MDNA

Belpointe Asset Management’s Medicenna Therapeutics Corp. Common Shares MDNA Stock Holding History

Belpointe Asset Management’s Portfolio MDNA Stock Details MDNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-10,249
Closed -$6.45K – 3640
2023
Q1 		$6.45K Hold
10,249
– – ﹤0.01% 2913
2022
Q4 		$4.69K Buy
+10,249
New +$6.26K ﹤0.01% 2956

Other funds holding MDNA

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
LBA
Letko, Brosseau & Associates Montreal, Quebec, Canada $6.2B AUM 38.92% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Belpointe Asset Management's MDNA Position: Q2 2023 in Review

Belpointe Asset Management sold out of Medicenna Therapeutics Corp. Common Shares (MDNA) in Q2 2023, closing a stake of 10,249 shares — an estimated $6.45K sold.

Belpointe Asset Management first reported a position in MDNA in Q4 2022 and held it in 2 quarters. The position peaked at $6.45K in Q1 2023. 27 funds tracked by Wall St. Rank hold MDNA as of Q2 2023.

  • Belpointe Asset Management reported no remaining Medicenna Therapeutics Corp. Common Shares position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 10,249 Medicenna Therapeutics Corp. Common Shares shares in Q2 2023, an estimated $6.45K.
  • Belpointe Asset Management first reported a position in Medicenna Therapeutics Corp. Common Shares in Q4 2022 and held it in 2 quarters.
  • Belpointe Asset Management's Medicenna Therapeutics Corp. Common Shares position peaked at $6.45K in Q1 2023.
  • 27 funds tracked by Wall St. Rank held Medicenna Therapeutics Corp. Common Shares as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.